Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule

BNP7787 (disodium 2,2′-dithio-bis-ethane sulphonate; Tavocept™) is a novel agent developed to protect against cisplatin (cis-diammine-dichloroplatinum(II))-associated chronic toxicities. In this study, we determined the recommended dose of BNP7787 when preceding a fixed dose of cisplatin, the pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Boven, E, Westerman, M, van Groeningen, C J, Verschraagen, M, Ruijter, R, Zegers, I, van der Vijgh, W J F, Giaccone, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362054/
https://www.ncbi.nlm.nih.gov/pubmed/15841080
http://dx.doi.org/10.1038/sj.bjc.6602553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362054/
https://www.ncbi.nlm.nih.gov/pubmed/15841080
http://dx.doi.org/10.1038/sj.bjc.6602553

Ejemplares similares